Detlef Krieter

Prof. Detlef Krieter

Dep. of Medicine I, Nephrology, University Hospital Würzburg, Oberdürrbacher Str. 6, 97080 Würzburg, Germany
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2009 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
DKDetlef Krieter
Detlef Krieter
AHAndrea Hackl
Andrea Hackl
ARAnnie Rodriguez
Annie Rodriguez
LCLeïla Chenine
Leïla Chenine
HMHélène Leray Moragues
Hélène Leray Moragues
BCBernard Canaud
Bernard Canaud
Background. The accumulation of larger and protein-bound toxins is involved in the uraemic syndrome but their elimination by dialysis therapy remains difficult. In the present study, the impact of the albumin permeability of recently introduced advanced high-flux dialysis membranes on the removal of such substances was tested in haemodialysis and online post-dilution haemodiafiltration. Methods. Two types of polyethersulfone membranes only differing in albumin permeability (referred as PU− and PU+) were compared in eight patients on maintenance dialysis in a prospective cross-over manner. Treatment settings were identical for individual patients: time 229 ± 22 min; blood flow rate 378 ± 33 mL/min; dialysate flow rate 500 mL/min; substitution flow rate in haemodiafiltration 94 ± 9 mL/min. Removal of the protein-bound compounds p-cresyl sulfate (pCS) and indoxyl sulfate (IS) was determined by reduction ratios (RRs), dialytic clearances and mass in continuously collected dialysate. In addition, the elimination of the low-molecular weight (LMW) proteins beta 2 -microglobulin, cystatin c, myoglobin (myo), free retinol-binding protein (rbp) and albumin was measured. Results. Plasma levels of the protein-bound toxins were significantly decreased by all treatment forms. However, the decreases were comparable between dialysis membranes and between haemodialysis and haemodiafiltration. The RRs of total pCS ranged between 40.4 ± 25.3 and 47.8 ± 10.3% and of total IS between 50.4 ± 2.6 and 54.6 ± 8.7%. Elimination of free protein-bound toxins as assessed by their mass in dialysate closely correlated positively with the pre-treatment plasma concentrations being r = 0.920 ( P < 0.001) for total pCS and r = 0.906 ( P < 0.001) for total IS, respectively. Compared to haemodialysis, much higher removal of all LMW proteins was found in haemodiafiltration. Dialysis membrane differences were only obvious in haemodialysis for the larger LMW proteins myo and rbp yielding significantly higher RRs for PU+ (myo 46 ± 9 versus 37 ± 9%; rbp 18 ± 5 versus 15 ± 5%; P < 0.05). Additionally, the albumin loss varied between membranes and treatment modes being undetectable with PU− in haemodialysis and highest with PU+ in haemodiafiltration (1430 ± 566 mg). Conclusions. The elimination of protein-bound compounds into dialysate is predicted by the level of pre-treatment plasma concentrations and depends particularly on diffusion. Lacking enhanced removal in online post-dilution haemodiafiltration emphasizes the minor significance of convection for the clearance of these solutes. Compared to LMW proteins, the highly protein-bound toxins pCS and IS are less effectively eliminated with all treatment forms. For a sustained decrease of pCS and IS plasma levels, alternative strategies promise to be more efficient therapy forms.

1 January 2005 in Kidney International
Verified
Journal Article
Open access
PDF file
DKDetlef Krieter
Detlef Krieter
SFSven Falkenhain
Sven Falkenhain
LCLotfi Chalabi
Lotfi Chalabi
GCGregory Collins
Gregory Collins
HLHorst-Dieter Lemke
Horst-Dieter Lemke
BCBernard Canaud
Bernard Canaud
At present, about 90 different uremic toxins have been identified, and this number certainly represents only a minority of toxins that accumulate during chronic renal failure and contribute to the uremic syndrome1 x 1. Vanholder, R., Glorieux, G., De Smet, R. et al. New insights in uremic toxins. Kidney Int. 2003; 63: S6–S10 https://doi.org/10.1046/j.1523-1755.63.s85.3.x Abstract | Full Text | Full Text PDF | Google Scholar See all References . Uremic toxins comprise a wide range of molecular weights. With low-flux hemodialysis (HD), small non–protein-bound solutes diffuse rapidly, and can pass easily through low-flux membranes while retaining middle- (500–15,000 Da) and large- (>15 kD) molecular weight molecules, also classified as low-molecular-weight (LMW) proteins. High-flux HD, using a more porous high-flux membrane, allows larger molecules to pass through the membrane. However, the quantity removed becomes internal filtration limited.

24 January 2014 in Toxins
Verified
Journal Article
Open access
PDF file
EDEric Devine
Eric Devine
DKDetlef Krieter
Detlef Krieter
MRMarieke Rueth
Marieke Rueth
JJJoachim Jankowski
Joachim Jankowski
HLHorst-Dieter Lemke
Horst-Dieter Lemke
Protein binding prevents uremic toxins from removal by conventional extracorporeal therapies leading to accumulation in maintenance dialysis patients. Weakening of the protein binding may enhance the dialytic elimination of these toxins. In ultrafiltration and equilibrium dialysis experiments, different measures to modify the plasma binding affinity and capacity were tested: (i), increasing the sodium chloride (NaCl) concentration to achieve a higher ionic strength; (ii), increasing the temperature; and (iii), dilution. The effects on the dissociation constant KD and the protein bound fraction of the prototypical uremic toxin indoxyl sulfate (IS) in plasma of healthy and uremic individuals were studied. Binding of IS corresponded to one site binding in normal plasma. KD increased linearly with the NaCl concentration between 0.15 (KD = 13.2 ± 3.7 µM) and 0.75 M (KD = 56.2 ± 2.0 µM). Plasma dilution further reduced the protein bound toxin fraction by lowering the protein binding capacity of the plasma. Higher temperatures also decreased the protein bound fraction of IS in human plasma. Increasing the NaCl concentration was effective to weaken the binding of IS also in uremic plasma: the protein bound fraction decreased from 89% ± 3% to 81% ± 3% at 0.15 and 0.75 M NaCl, respectively. Dilution and increasing the ionic strength and temperature enhance the free fraction of IS allowing better removal of the substance during dialysis. Applied during clinical dialysis, this may have beneficial effects on the long-term outcome of maintenance dialysis patients.

12 November 2012 in Artificial Organs
Verified
Journal Article
Open access
PDF file
DKDetlef Krieter
Detlef Krieter
BCBernard Canaud
Bernard Canaud
HLHorst‐Dieter Lemke
Horst‐Dieter Lemke
ARAnnie Rodriguez
Annie Rodriguez
AMAndreas Morgenroth
Andreas Morgenroth
CWChristoph Wanner
Christoph Wanner
The estrogenic endocrine‐disrupting substance bisphenolA(BPA) is extensively used as a starting material for a variety of consumer plastic products including dialyzer materials. The present study was performed to explore plasmaBPAlevels in patients with impaired renal function and to investigate if dialyzers differing in elutableBPAinfluence plasma levels in patients on maintenance hemodialysis. In vitroBPAwas eluted from high‐flux polyethersulfone (PUREMA H, referred asPUR‐H), high‐flux polysulfone (referred asHF‐PSu), and low‐flux polysulfone (referred asLF‐PSu) dialyzers by recirculation with water for 180 min. In a cross‐sectional clinical study, plasmaBPAlevels of outpatients with different stages of chronic kidney disease (CKD) from four different centers were determined. Furthermore, in a prospective, randomized, and crossover setting, 18 maintenance dialysis patients were subjected successively to 4 weeks of thrice‐weekly hemodialysis with eachLF‐PSu,HF‐PSu, andPUR‐H. In addition, the fractions of protein‐bound and freeBPAwere determined in a subset of dialysis patients. The mass ofBPAeluted from the blood compartments in vitro under aqueous conditions varied for the three dialyzers being very low forPUR‐H(6.2 ± 2.5 ng;P < 0.001), intermediate forHF‐PSu(48.1 ± 7.7 ng), and highest forLF‐PSu(140.8 ± 38.7 ng;P < 0.01). In 152 prevalent patients withCKDenrolled in the cross‐sectional trial, plasmaBPAstarted to rise after stage 3. Maintenance hemodialysis patients had more than six times higherBPAconcentrations than patients withCKDstage 5 not yet on dialysis (10.0 ± 6.6 vs. 1.6 ± 1.8 ng/mL;P < 0.001). TheBPAconcentrations highly and inversely correlated with renal function. In the randomized controlled study, the plasmaBPAconcentrations were highly elevated compared with healthy controls (range 9.1 ± 4.5–12.0 ± 6.0 ng/mL vs. ≤0.2 ± 0.1 ng/mL;P < 0.001), but no change of the plasma levels was observed during hemodialysis with any of the three dialyzers in the course of a single treatment and over a period of 4 weeks. The protein‐bound fraction of plasmaBPAin the dialysis patients was 74 ± 5%. Renal function and, most likely, the total quantity of ingestedBPAare essential parameters affecting plasmaBPAconcentrations. Dialyzers are one additional source ofBPA, but differences in the elutableBPAcontent are not associated with a significant effect onBPAplasma levels in Western European maintenance dialysis patients. Due to high protein binding, the removal ofBPAby hemodialysis is limited.

22 June 2016 in Acta Physiologica
Verified
Journal Article
Closed access
PDF file
DKDetlef Krieter
Detlef Krieter
EDEric Devine
Eric Devine
TKThomas Körner
Thomas Körner
MRMarieke Rueth
Marieke Rueth
CWChristoph Wanner
Christoph Wanner
HLHorst‐Dieter Lemke
Horst‐Dieter Lemke

16 January 2019 in Toxins
Verified
Journal Article
Open access
PDF file
DKDetlef Krieter
Detlef Krieter
SKSimon Kerwagen
Simon Kerwagen
MRMarieke Rueth
Marieke Rueth
HLHorst-Dieter Lemke
Horst-Dieter Lemke
CWChristoph Wanner
Christoph Wanner
The protein-bound uremic toxins para-cresyl sulfate (pCS) and indoxyl sulfate (IS) are associated with cardiovascular disease in chronic renal failure, but the effect of different dialysis procedures on their plasma levels over time is poorly studied. The present prospective, randomized, cross-over trial tested dialysis efficacy and monitored pre-treatment pCS and IS concentrations in 15 patients on low-flux and high-flux hemodialysis and high-convective volume postdilution hemodiafiltration over six weeks each. Although hemodiafiltration achieved by far the highest toxin removal, only the mean total IS level was decreased at week three (16.6 ± 12.1 mg/L) compared to baseline (18.9 ± 13.0 mg/L, p = 0.027) and to low-flux dialysis (20.0 ± 12.7 mg/L, p = 0.021). At week six, the total IS concentration in hemodiafiltration reached the initial values again. Concentrations of free IS and free and total pCS remained unaltered. Highest beta2-microglobulin elimination in hemodiafiltration (p < 0.001) led to a persistent decrease of the plasma levels at week three and six (each p < 0.001). In contrast, absent removal in low-flux dialysis resulted in rising beta2-microglobulin concentrations (p < 0.001). In conclusion, this trial demonstrated that even large differences in instantaneous protein-bound toxin removal by current extracorporeal dialysis techniques may have only limited impact on IS and pCS plasma levels in the longer term.